The Pharmacy Place Review: What Its Compounded GLP-1 Program Documents—and What It Does Not

A pharmacy can document how it takes an order without demonstrating how well its particular formulation works. That distinction is central to The Pharmacy Place, a Peachtree City, Georgia, business advertising compounded semaglutide and tirzepatide injections alongside coordinated telemedicine. Its public pages describe physician review, in-house preparation, included injection supplies and temperature-controlled shipping. Those are useful operational details, but they answer different questions from clinical research on treatment outcomes.

This review examines public documentation consulted October 19, 2026, separating the pharmacy’s representations from independent clinical context. The offering is more specific than a generic medication referral service: The Pharmacy Place identifies a physical pharmacy, named staff and a checkout-to-prescription process. Important gaps remain, including the full state-service list, the clinical partner’s identity, follow-up arrangements and refund conditions. Its advertised prices also need careful interpretation because monthly program language does not consistently match product-page pricing or package duration.

At a glance

Documented business: The Pharmacy Place describes itself as a compounding pharmacy in Peachtree City, Georgia, preparing customized medications and weight-management treatments in-house.
Sources: [10]
Products and regulatory status: The program advertises compounded semaglutide and tirzepatide injections enhanced with B vitamins. Compounded preparations are not FDA approved.
Sources: [11] [1]
Published prices: The program page lists semaglutide starting at $139/month, rising to $179/month depending on dose, and tirzepatide starting at $179/month, rising to $279/month. The tirzepatide product page instead displays $179–$299 without defining the supply period in its price heading.
Sources: [11] [6]
Included services: Product pages include shipping, injection supplies and a doctor consultation valued at $20 in the displayed price. The pharmacy advertises no membership, minimum or commitment.
Sources: [9] [6] [10]
Geographic limit: The homepage describes current service throughout the Southeast and nationwide expansion as a future plan. Another page asks patients to contact the pharmacy to confirm state availability.
Sources: [10] [7]

Start with the pharmacy, not the outcome claims

The Pharmacy Place identifies its location as 2035 Commerce Dr N, Peachtree City, GA 30269, and lists 678-271-3970 as its general telephone number. Its homepage names Hiren Patel as founder, pharmacist and owner. The published team also includes Charley Nowicki, clinical pharmacist liaison; Tiffany Turner, pharmacist; and Neil Patel, compounding lead technician. These details identify the business and staff roles, but they do not independently establish licensing status or clinical performance.

The company says it is a fully licensed compounding pharmacy rather than a middleman and that it prepares medication in-house. It also describes itself as LegitScript-certified and compliant with applicable laws and advertising standards. Those are provider statements, not credential checks performed for this review. A named pharmacy and an identified preparation site make the service easier to investigate, but neither is a substitute for verification of the credentials relevant to a particular patient’s state.

This distinction matters because the website combines operational statements with claims about quality and treatment benefits. Public pages can establish what a business represents it will provide; they cannot, by themselves, establish that its formulation produces a particular result. Our guide to what provider documentation can prove explains that boundary. Here, the most concrete documentation concerns the pharmacy’s identity, ordering process, advertised charges and shipping arrangements—not independently measured patient outcomes.

Sources: [10] [7]

What is documented about the injectable formulations

The program describes compounded semaglutide and tirzepatide administered by injection under the skin. It says patients will be taught how to prepare and administer the medication. The injections are advertised as enhanced with B vitamins, with associated claims about energy, metabolism and weight loss. The consulted documentation does not specify the exact B vitamins or the composition of each product, so those promotional statements should not be treated as a complete formulation description.

The pharmacy explicitly states that compounded medications are not FDA approved and are not evaluated by FDA for safety, effectiveness or quality. FDA approval belongs to a specific product, not to a pharmacy or an ingredient name in isolation. Nonapproval alone does not establish clinical inequivalence, but it also does not establish equivalence. The relevant question is what evidence supports the actual preparation being prescribed, including its ingredients, presentation and route.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a blanket conclusion about this business or an individual’s eligibility. Before paying, a useful request is a written description of the proposed preparation and the clinician’s reason for selecting it. Our explanation of approved medicines and compounded preparations separates these regulatory and evidence questions.

Sources: [11] [1]

Clinical research does not validate this pharmacy’s vitamin blends

The independent clinical context includes STEP 1, a randomized semaglutide trial, and SURMOUNT-1, a randomized tirzepatide trial. Neither was a study of The Pharmacy Place or its compounded products. Their findings therefore cannot establish this pharmacy’s treatment outcomes, the performance of its vitamin blends or the result an individual customer should expect. The consulted material provides no provider-specific clinical study measuring outcomes for the formulations advertised here.

That limitation applies particularly to the pharmacy’s claims that B-vitamin-enhanced injections boost energy and keep metabolism on track. These are commercial descriptions, not independent findings about the advertised blends. Evidence associated with a medication name should not silently transfer to every preparation bearing that name. Nor should results from separate trials become a head-to-head ranking of this pharmacy’s semaglutide and tirzepatide options. The distinction is explained further in why a trial is not a company performance report.

An evidence-focused consultation should address benefits, side effects, existing conditions, other medicines and cost, rather than relying on a promotional outcome claim. NIDDK describes medication as accompanying healthy eating and physical activity, with follow-up addressing response and tolerability. For this provider, the unresolved question is how that ongoing clinical assessment is organized. A pharmacy’s availability to answer questions is useful, but it does not document a scheduled prescriber review or a complete monitoring plan.

Sources: [3] [4] [2] [11] [10]

Checkout comes before the product-page medical questionnaire

The Pharmacy Place says its telehealth platform coordinates prescriptions with a provider specializing in weight management. Its program description says patients complete an online form covering health, lifestyle and medical history; a licensed physician then reviews the information, develops a treatment plan and prescribes if appropriate. Although another passage says patients will receive either semaglutide or tirzepatide based on assessment, the conditional approval language is important: completing the process does not establish entitlement to a prescription.

The product pages add a consequential ordering detail: the secure medical-questionnaire link arrives after checkout. They say an approved prescription is sent directly to the compounding pharmacy, where processing begins. This establishes the stated sequence, but not what happens financially if the physician declines treatment. The consulted documentation does not clearly explain whether checkout authorizes or collects a charge, when that charge becomes final, or how a clinical denial affects any payment already made.

The advertised eligibility description is adults 18 or older who are not pregnant or breastfeeding and do not have certain conditions that could make treatment unsafe. It is not a complete clinical screening policy. The pages do not establish specific excluded conditions, laboratory requirements or full eligibility thresholds, and they do not identify the outside clinical entity or individual evaluating physicians. Readers should obtain those details without treating a general eligibility statement as personal medical clearance.

Sources: [11] [9]

The prices are visible, but the units need reconciliation

The program is advertised as cash-pay, with no insurance required. Its informational page lists compounded semaglutide starting at $139 per month and rising to $179 per month depending on dose. Compounded tirzepatide starts at $179 per month and rises to $279 per month there. The tirzepatide product page instead shows a $179–$299 range. That $299 upper figure should not be hidden behind a general statement that pricing varies; it is a documented discrepancy requiring confirmation.

The product-page headings do not independently establish a supply period. In addition, the semaglutide listing distinguishes an initial six-week supply from other four-week options. Four weeks is not a calendar month, and a package duration does not establish either a minimum commitment or a specific quantity beyond what the selected option documents. Ask for the exact formulation, presentation, supply duration and final charge together; a monthly headline alone is insufficient to identify the purchase.

Both product listings include injection supplies, free shipping and a doctor consultation identified as worth $20 within the price. The program page says there are no membership, consultation, shipping or hidden fees; the homepage also advertises no minimums or commitments. Those statements describe an appealingly simple offer, but they do not settle recurring-charge authorization, renewal timing or later clinical-visit charges. No introductory-versus-renewal schedule or price-lock promise is established by the consulted documentation.

Published price statements and what to clarify before checkout
Offering or term	What the pages say	What still needs confirmation
Compounded semaglutide injections: program page	Starts at $139/month; up to $179/month depending on dose	Which presentation and supply duration match the quoted charge
Compounded semaglutide injections: product page	$139–$179; initial six-week and other four-week options are distinguished	Selected option, quantity and subsequent purchase price
Compounded tirzepatide injections	Program: $179–$279/month; product page: $179–$299	Why the maximum differs and what period the product price covers
Included services	Shipping, injection supplies and a consultation valued at $20 included	Scope and charges, if any, for later clinical encounters
Ongoing purchase terms	No membership, minimum or commitment advertised	Whether billing recurs automatically and how future orders are stopped

Sources: [10] [11] [6] [9]

State access and clinical support remain separate questions

The homepage says The Pharmacy Place currently serves patients throughout the Southeast and plans nationwide expansion. Another page states that it is licensed in multiple states and asks patients to contact the business to confirm their own state. A broader promotional reference to patients across the country does not resolve that narrower description. The consulted documentation does not establish nationwide availability or provide a complete state list and license numbers for independent verification.

There are two documented telephone routes: the general pharmacy number, 678-271-3970, and the program-page number, 833-586-3111. The program page says a pharmacist is on staff to answer questions, while the homepage promises ongoing pharmacy-team support. These statements establish contact options, not guaranteed response times or a prescriber appointment schedule. The documentation also does not confirm Spanish-language service, interpretation, support hours or how a clinical concern is escalated from pharmacy staff to the prescribing clinician.

Before completing checkout, readers can use those contacts to confirm both pharmacy service and telehealth access in their state, identify the clinical organization, and request the follow-up process in writing. The important distinction is responsibility: medication questions may be handled by a pharmacist, while treatment decisions require the appropriate clinician. Our guide to clinical follow-up beyond renewal notices explains why a support promise should not be mistaken for a documented longitudinal care plan.

Sources: [10] [7] [11] [2]

Shipping claims describe several different clocks

The homepage says most orders ship within one to two business days after prescription approval. The program page separately says the physician typically sends the prescription within one to two days of the consultation. It then says morning prescriptions usually ship the same day and afternoon prescriptions the following business day. These statements concern different stages. None should be substituted for a guaranteed consultation-to-doorstep interval, especially while clinical review or prescription transmission is still pending.

The program also says most patients receive medication within 72 hours of the online consultation. That is a provider estimate, not a delivery guarantee. Shipping is described as UPS Next-Day in temperature-controlled packaging, with syringes and alcohol swabs included. Product pages promise an in-process notification and tracking information once the order ships. Together, these details explain the intended logistics, but they do not establish actual delivery performance or verify the temperature history of an individual package.

For lost or delayed packages, the pharmacy instructs customers to contact it immediately. FDA additionally advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. A general website statement about stability cannot verify a particular shipment. Readers should ask in advance how temperature concerns are assessed, who authorizes a replacement and whether a replacement or refund would involve an additional charge.

Sources: [10] [11] [6] [1]

Refunds and recurring care need written answers

The pharmacy states that it cannot accept medications back once they have left its facilities. This is a return restriction, not a complete refund policy. It does not establish what happens after clinical denial, cancellation before dispatch, a missing package or a quality complaint. Likewise, the advertised absence of commitments does not itself explain cancellation mechanics or entitle a customer to repayment. Those boundaries matter particularly because the product-page questionnaire follows checkout rather than preceding it.

The privacy policy provides a more explicit rule for marketing: consent to commercial messages is not required to purchase, and consent can be withdrawn. SMS recipients can reply STOP, although administrative communications may continue. Ending marketing messages is not the same as canceling an order, ending a payment authorization or transferring clinical care. Readers should keep those processes separate and ask for the specific contact and confirmation required to stop any future purchases.

The website’s terms acknowledge that materials may contain errors and may not be accurate, complete or current. That disclaimer does not erase the published offer, but it reinforces the value of a written, order-specific confirmation. The most useful record would combine the selected preparation, final price, supply duration, state eligibility, payment timing, prescriber identity and refund rules. For clinical continuity, it should also explain reassessment, prescription renewal and how questions about response or side effects reach the clinician.

Sources: [11] [9] [10] [5] [8] [2]

Questions & answers

Does The Pharmacy Place sell FDA-approved GLP-1 products through this program?

The reviewed program advertises compounded semaglutide and tirzepatide injections, not a documented offering of specific FDA-approved branded products. The pharmacy itself discloses that compounded medications are not FDA approved. This does not establish clinical inequivalence, but research on another product does not validate its preparations. Ask the prescriber to identify the exact proposed product and explain why a compounded preparation is being considered for your medical needs.

Sources: [11] [1]

What should I expect to pay for tirzepatide?

The program page advertises compounded tirzepatide starting at $179 per month and going up to $279 per month. The product page displays $179–$299, without defining the supply period in that price heading. Shipping, injection supplies and a doctor consultation valued at $20 are listed as included. Before checkout, request the final price for the selected presentation and duration, plus an explanation of the differing upper prices.

Sources: [11] [6]

Will I complete the medical assessment before paying?

The product pages say a secure questionnaire link is sent after checkout. They also say prescription issuance depends on approval. The documentation does not clearly establish the exact payment-capture timing or the refund treatment if approval is declined. Ask whether checkout collects money immediately, what happens if no prescription is issued, and whether any consultation amount is retained. Do not assume the included consultation makes a denied application automatically refundable.

Sources: [9]

Can The Pharmacy Place serve me outside Georgia?

Possibly, but the public documentation does not provide a complete answer for every state. The homepage describes current service throughout the Southeast, while another page says the pharmacy holds licenses in multiple states and asks customers to contact it. Nationwide expansion is described as a plan, not established current coverage. Confirm both pharmacy delivery and the prescribing service’s availability for your state before checking out, rather than relying on broad promotional language.

Sources: [10] [7]

What if my shipment is late or arrives warm?

The pharmacy asks customers to contact it immediately about lost or delayed packages. It advertises UPS Next-Day temperature-controlled shipping, but its various timing estimates are not guarantees. FDA advises not using an injectable GLP-1 medication that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. The consulted pages do not establish a detailed replacement or refund policy for these circumstances, so request one before ordering.

Sources: [11] [1]

Does no membership mean no ongoing clinical obligations or repeat charges?

The pharmacy advertises no memberships, minimums or commitments. That does not establish whether a payment method is authorized for recurring charges, how repeat orders work or when prescriptions need reassessment. Nor does it eliminate the clinical need to review response and tolerability. Ask separately about future billing, stopping orders, clinician follow-up and renewal requirements. Ongoing pharmacy support is documented; a specific schedule of included prescriber visits is not.

Sources: [10] [2]

Our assessment

The Pharmacy Place provides useful operational detail: an identified Georgia pharmacy, named staff, physician review before prescribing, stated in-house preparation, visible cash-pay ranges and included shipping and supplies. Those features make its offer assessable, but they are not clinical validation of its compounded vitamin blends. The strongest unresolved issues are the tirzepatide price discrepancy, differing supply periods, checkout-before-questionnaire sequence, incomplete state coverage information and absent detailed refund and follow-up terms. A practical next step is to request one written explanation covering the exact preparation, charge, duration, approval outcome, delivery remedies and responsible clinician. The documentation supports describing a pharmacy-led compounded GLP-1 service—not promising its results, nationwide access or a fully specified continuing-care arrangement.

Visit The Pharmacy Place’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

The Pharmacy Place Review: What Its Compounded GLP-1 Program Documents—and What It Does Not

At a glance

01Start with the pharmacy, not the outcome claims

02What is documented about the injectable formulations

03Clinical research does not validate this pharmacy’s vitamin blends

04Checkout comes before the product-page medical questionnaire

05The prices are visible, but the units need reconciliation

06State access and clinical support remain separate questions

07Shipping claims describe several different clocks

08Refunds and recurring care need written answers

Questions & answers

Our assessment

Sources & documentation

Continue reading

Start with the pharmacy, not the outcome claims

What is documented about the injectable formulations

Clinical research does not validate this pharmacy’s vitamin blends

Checkout comes before the product-page medical questionnaire

The prices are visible, but the units need reconciliation

State access and clinical support remain separate questions

Shipping claims describe several different clocks

Refunds and recurring care need written answers